🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Diabetic Retinopathy Screening, Prevention and Control Program

Recruitingn/aAges 18 Years - anyAllShanghai Jiao Tong University School of Medicine
NCT04240652 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The greatest harm of diabetes is various acute and chronic complications, especially diabetic retinopathy(DR), leading to extremely high rates of disability and blindness. Early screening, early diagnosis, and early treatment are the keys to maintaining vision in patients with DR. However, compared with the high prevalence of diabetes in China, the DR screening ability is relatively inadequate. To change this situation, deep learning(DL), a form of artificial intelligence (AI), might be a potential effective method to solve this dilemma.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Meet the diagnostic criteria for type 2 diabetes according to the World Health Organization (WHO) in 1999; Type 1 diabetes, single gene mutation diabetes, secondary diabetes caused by pancreatic damage, Cushing's syndrome, thyroid dysfunction, or acromegaly; * Subjects from other medical institutes are diabetes, non-diabetic patients and healthy participants who are invited to participate in the study. Exclusion Criteria: * Those who have a history of drug abuse; * Sexually transmitted diseases such as AIDS and syphilis, and infectious diseases such as viral hepatitis and tuberculosis which are at active phase; * Any condition that the investigator think that the subject is not suitable for participating in the study. For detailed In-/Ex-clusion criteria please see the study protocol.
💊

What it tests

  • Not listed
📍

Where

2 sites
Ruijin hospital, Shanghai Jiao-Tong University School of Medicine
Shanghai, China
Shanghai Jiao-Tong University School of Medicine
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy